Read this company snapshot
Daily valuation snapshot
Citius Pharmaceuticals Inc. Common: source evidence dated 2026-10-09.
- Daily close (USD)
- $0.5
- Market capitalization (USD)
- $13,709,813.46
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.18
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CTXR in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CTXR in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing CTXR with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $0.5 |
| Market capitalization (USD) | $13,709,813.46 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.18 |
No matching rows. Clear the filter to see all records.
Read CTXR's valuation metrics
Company size
Citius Pharmaceuticals Inc. Common's recorded market capitalization is $13,709,813.46. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
CTXR's recorded price-to-book ratio is 0.18. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Citius Pharmaceuticals Inc. Common with Aurora
Use the snapshot above to ask a specific question about CTXR. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CTXR's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.